Strengthening Regulatory Oversight of Digital Pharmaceutical Supply Chains in the United Arab Emirates

Abstract

The transformation of traditional pharmaceutical supply chain to modern digital platform creates cross-border distribution pathways challenging the conventional regulatory oversight. Although the existing frameworks provide the necessary controls over manufacturers, importers, authorized establishments, product identity and supply-chain traceability, online commerce introduces additional complexities at the point where a digital transaction becomes a physical cross-border shipment. This perspective proposes a regulatory verification layer to complement the existing pharmaceutical authentication, serialization, track-and-trace and online-seller verification mechanisms. The proposal would connect existing Emirates Drug Establishment authorization and import records, Tatmeen traceability information and customs processes.
In practice, this status could be represented by a QR code or equivalent machine-readable conformity mark accompanying the shipment, enabling rapid verification without requiring the intermediary to access the underlying regulatory record. Digital platforms and logistics providers would perform narrowly defined verification functions before fulfilment or carriage, while regulatory assessment, authorization, interpretation and enforcement would remain with the competent authority. The article distinguishes regulatory eligibility from product authentication and traceability, and examines cross-border recognition, interoperability, accountability, enforcement, cost, data governance and potential unintended consequences. The proposed model offers a risk-based and potentially scalable mechanism to connect regulatory authorization with digital fulfilment without transferring substantive regulatory authority to private intermediaries.